Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q4 2015 · 10-K
Revenue$8.04M$8.04M−13.8% vs Q4 2014 Net Income$151.06K$151.06K−77.4% vs Q4 2014 EPS Diluted$0.01$0.01−75.0% vs Q4 2014 Operating Income$162,679−82.8% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,277,172−53.1% Margins · derivedOperating margin2.0%−8.1 pt vs Q4 2014
Net margin1.9%−5.3 pt vs Q4 2014
ended Dec 31, 2015 · filed Mar 14, 2016 · 74 d after period end